scholarly journals Correlation of HER-2/neu Status with Estrogen (ER) & Progesterone (PR) Receptor in Breast Malignancies

2020 ◽  
Vol 34 (1) ◽  
pp. 30-38
Author(s):  
Asma Rasheed
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Inverse Correlation ◽  
Lymph Node Status ◽  
Medical Institute ◽  
Positive Correlation ◽  
Infiltrating Ductal Carcinoma ◽  
Er Positive ◽  
Her 2 ◽  
Breast Malignancies

Introduction: Prognosis and management of breast cancer are influenced by the classic variables such as histologic type and grade, tumor size, lymph node status, status of hormonal receptors- i.e. estrogen receptor (ER) and progesterone receptor (PR) of the tumor, and, more recently, HER-2/neu (Human Epidermal Growth factor Receptor-2) overexpression. Expression levels of the estrogen, progesterone and HER2/neu receptors which characterize clinically distinct breast tumours have been shown to change during disease progression and in response to systemic therapies. The interrelationship of ER, PR, and HER -2 has come to have a crucial role in the management of breast cancer. Aims & Objectives: To determine the ER, PR and HER2/neu status in breast malignancies. Place and duration of study: The study was conducted at Department of Histopathology, Federal Postgraduate Medical Institute, Shaikh Zayed Hospital Lahore, for the period of Six months. Material & Methods: 30 samples of diagnosed breast cancer were included in study. Formalin fixed paraffin embedded wax block were taken for immunohistochemical staining of ER, PR & HER-2/neu. Results: Out of 30 cases, racially 29 were Punjabi and 1 was Pakhtun. There were 23 mastectomy samples and 7 needle core biopsies. Out of 30 cases, 29 were Infiltrating Ductal Carcinoma. Grade I, II, III 13.3%, 66. 7% and 20% respectively and only one case was of Carcinosarcoma (p<0.01). Overall immunoexpression for ER, PR and HER-2/neu were 33.3% (p<0.01), 56.7% (p<0.05) and 73.3% respectively. Triple positive (TP) cases were 23.3% and triple negative (TN) were 10 %. Regarding ER expression in infiltrating ductal carcinoma, 63.3% were ER negative and 33.3% were ER positive and comparison was statistically highly significant (p<0.01) .PR expression in infiltrating ductal carcinoma showed 56.7% PR positive and 40% PR negative which was statistically significant (p<0.05).There is negative correlation of HER-2/neu positive and ER positive and positive correlation of HER-2/neu positive and PR positive cases. Conclusion: There is inverse correlation of HER-2/neu positive and ER positive and positive correlation of HER-2/neu positive and PR positive cases.

scholarly journals Overexpression of SOX2 is associated with poor prognosis in human breast cancer

2021 ◽  
Vol 2 (3) ◽  
Author(s):  
Raquel C Rodrigues ◽  
◽  
Camila P Almeida ◽  
Milena C M Oliveira ◽  
Enio Ferreira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Human Breast Cancer ◽  
Poor Prognosis ◽  
Ductal Carcinoma ◽  
Lymph Node Status ◽  
Human Breast ◽  
Sox2 Expression ◽  
Potential Biomarker ◽  
Her 2

SOX2 is a transcription factor that activates or suppresses genes involved in cellular differentiation, proliferation, and apoptosis. The deregulation of gene expression programs can lead to cancer initiation, promotion, and progression. The present study investigated SOX2 immunolocalization and expression in Invasive Ductal Carcinoma (IDC), and its correlation with clinical-pathological characteristics of the tumor. Immunohistochemical expression of SOX2 was evaluated in 19 cases of IDC and correlated with clinical-pathological tumor features. To investigate the correlation of SOX2 expression in IDC with other characteristics of human breast cancer, the same samples were also stained with immunohistochemical prognostic panels (estrogen and progesterone receptors, and HER-2). SOX2 overexpression was observed in 44% of the cases. Higher SOX2 expression was correlated with the worst lymph node status (p<0.001) and with positive HER-2 immunostaining (p<0,001). The present study demonstrated the association of SOX2 and tumors with worse TNM staging, as well as its overexpression in positive HER-2 tumors. In conclusion, SOX2 was identified as a potential biomarker for poor prognosis of human breast cancer. Further studies with higher patient numbers are necessary to investigate and help clarify the mechanisms underlying this association. Keywords: SOX2; HER-2; Breast cancer; IHC; Invasive ductal carcinoma; Prognosis.

scholarly journals Induction of Apoptosis in MDA-MB-231 Cells Treated with the Methanol Extract of Lichen Physconia hokkaidensis

2021 ◽  
Vol 7 (3) ◽  
pp. 188
Author(s):  
Ji-In Noh ◽  
Seul-Ki Mun ◽  
Eui Hyeon Lim ◽  
Hangun Kim ◽  
Dong-Jo Chang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Prolonged Exposure ◽  
Methanol Extract ◽  
Growth Factor Receptor ◽  
Annexin V ◽  
Er Positive ◽  
Her 2 ◽  
Induction Of Apoptosis ◽  
Mcf 7

Physconia hokkaidensis methanol extract (PHE) was studied to identify anticancer effects and reveal its mechanism of action by an analysis of cytotoxicity, cell cycles, and apoptosis biomarkers. PHE showed strong cytotoxicity in various cancer cells, including HL-60, HeLa, A549, Hep G2, AGS, MDA-MB-231, and MCF-7. Of these cell lines, the growth of MDA-MB-231 was concentration-dependently suppressed by PHE, but MCF-7 was not affected. MDA-MB-231 cells, triple-negative breast cancer (TNBC) cells, do not express estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2), whereas MCF-7 cells are ER-positive, PR-positive, and HER-2-negative breast cancer cells. The number of cells in sub-G1 phase was increased after 24 h of treatment, and annexin V/PI staining showed that the population size of apoptotic cells was increased by prolonged exposure to PHE. Moreover, PHE treatment downregulated the transcriptional levels of Bcl-2, AMPK, and p-Akt, whereas it significantly upregulated the levels of cleaved caspase-3, cleaved caspase-9, and cleaved-PARP. In conclusion, it was confirmed that the PHE exhibited selective cytotoxicity toward MDA-MB-231, not toward MCF-7, and its cytotoxic activity is based on induction of apoptosis.

Uncommon Breast Malignancies: Presentation Pattern, Prognostic Issue and Treatment Outcome in an Italian Single Institution Experience

2013 ◽  
Vol 99 (1) ◽  
pp. 39-44
Author(s):  
Claudia Maria Regina Bareggi ◽  
Dario Consonni ◽  
Barbara Galassi ◽  
Donatella Gambini ◽  
Elisa Locatelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Outcome ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Medullary Carcinoma ◽  
Mucinous Carcinoma ◽  
Lymph Node Involvement ◽  
Tubular Carcinoma ◽  
Breast Malignancies

Aims and background Often neglected by large clinical trials, patients with uncommon breast malignancies have been rarely analyzed in large series. Patients and methods Of 2,052 patients diagnosed with breast cancer and followed in our Institution from January 1985 to December 2009, we retrospectively collected data on those with uncommon histotypes, with the aim of investigating their presentation characteristics and treatment outcome. Results Rare histotypes were identified in 146 patients (7.1% of our total breast cancer population), being classified as follows: tubular carcinoma in 75 (51.4%), mucinous carcinoma in 36 (24.7%), medullary carcinoma in 25 (17.1%) and papillary carcinoma in 10 patients (6.8%). Whereas age at diagnosis was not significantly different among the diverse diagnostic groups, patients with medullary and papillary subtypes had a higher rate of lymph node involvement, similar to that of invasive ductal carcinoma. Early stage diagnosis was frequent, except for medullary carcinoma. Overall, in comparison with our invasive ductal carcinoma patients, those with rare histotypes showed a significantly lower risk of recurrence, with a hazard ratio of 0.28 (95% CI, 0.12–0.62; P = 0.002). Conclusions According to our analysis, patients with uncommon breast malignancies are often diagnosed at an early stage, resulting in a good prognosis with standard treatment.

Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers

2008 ◽  
Vol 26 (6) ◽  
pp. 897-906 ◽  
Author(s):  
Marta Guix ◽  
Nara de Matos Granja ◽  
Ingrid Meszoely ◽  
Theresa B. Adkins ◽  
Bobbye M. Wieman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Tumor Cell ◽  
Growth Factor Receptor ◽  
Preoperative Treatment ◽  
Breast Cancers ◽  
Tumor Cell Proliferation ◽  
Hormone Receptor Positive ◽  
Er Positive ◽  
Her 2

Purpose To administer the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to patients with operable untreated breast cancer during the immediate preoperative period and to measure an antiproliferative and/or a proapoptotic effect in the post-therapy specimen and determine a biomarker profile associated with evidence of erlotinib-mediated cellular activity. Patients and Methods Newly diagnosed patients with stages I to IIIA invasive breast cancer were treated with erlotinib 150 mg/d orally for 6 to 14 days until the day before surgery. Erlotinib plasma levels were measured by tandem mass spectrometry the day of surgery. Drug-induced changes in tumor cell proliferation and apoptosis were assessed by Ki67 immunohistochemistry and terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate-biotin nick-end labeling analysis, respectively, in biopsies from the pretherapy and surgical specimens. Biopsies were also evaluated for P-EGFR, P-HER-2, P-MAPK, P-Akt, P-S6, and S118 P-ERα. Results In drug-sensitive PC9 xenografts, 5 days of treatment with erlotinib were enough to induce a maximal inhibition of cell proliferation and induction of apoptosis. Forty-one patients completed preoperative treatment with erlotinib. Grade ≤ 2 rash and diarrhea were the main toxicities. Erlotinib inhibited tumor cell proliferation (Ki67), P-EGFR, and P-HER-2. The inhibition of proliferation occurred in estrogen receptor (ER) –positive but not in human epidermal growth factor receptor 2 (HER-2) –positive or triple-negative cancers. Treatment was associated with a significant reduction of P-MAPK, P-Akt, P-S6, and S118 P-ERα in hormone receptor–positive cancers. Conclusion A presurgical approach to evaluate cellular responses to new drugs is feasible in breast cancer. EGFR inhibitors are worthy of testing against ER-positive breast cancers but are unlikely to have clinical activity against HER-2–positive or triple-negative breast cancers.

scholarly journals LACTOFERRIN EXPRESSION IN BREAST CANCER IN RELATION TO BIOLOGIC PROPERTIES OF TUMORS AND CLINICAL FEATURES OF DISEASE

2016 ◽  
Vol 38 (3) ◽  
pp. 181-186 ◽  
Author(s):  
L A Naleskina ◽  
N Yu Lukianova ◽  
S O Sobchenko ◽  
D M Storchai ◽  
V F Chekhun
Keyword(s):  
Breast Cancer ◽  
Clinical Features ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Strongly Correlated ◽  
Luminal A ◽  
Clinical Criteria ◽  
Luminal B ◽  
Course Materials ◽  
Er Positive

Aim: To determine the patterns of lactoferrin (LF) expression in breast cancer (BC) in relation to biologic properties of the neoplasms and clinical features of the disease course. Materials and Methods: Clinical specimens of 266 BC patients (115 patients with BC of stages I–II — retrospective study, and 151 BC patients — prospective study) were analyzed. Morphological, immunohistochemical and statistical methods were used. Results: The number of LF-positive tumors in retrospective and prospective groups was similar (52.1 and 52.8%, respectively). Among common clinical criteria for prognosis of the disease outcome in BC patients (patient’s age; stage of the disease; histological type, differentiation grade, receptor status; presence of metastases), a strong correlation was found only between expression indexes of LF and estrogen receptors (ER). In ER-positive tumors expression of LF was significantly higher than in ER-negative tumors (35 vs 18%). 5-Year survival rate of BC patients was higher in LF-positive group (70 vs 52% in LF-negative group). The presence of regional metastasis tended to correlate with an increased number of LF-positive tumors. In the patients with invasive ductal carcinoma, expression level of LF moderately correlated with occurrence of luminal A subtype (r = 0.43), while in the patients with invasive lobular carcinoma this index strongly correlated with occurrence of luminal B subtype (r = 0.71). LF expression correlated positively with low and moderate differentiation grade of luminal B or basal tumors, and negatively with luminal B or basal tumors of high differentiation grade (r = −0.57 and −0.63, respectively). Conclusion: It has been shown that LF expression in breast tumors correlated with life expectancy of BC patients and important physiologic and clinical features of the disease, while the character of such relation strongly depended on molecular phenotype of tumor, i.e. luminal A, luminal B or basal.

scholarly journals The Differential Expression of Aqueous Soluble Proteins in Breast Normal and Cancerous Tissues in Relation to Ethnicity of the Patients; Chinese, Malay and Indian

2010 ◽  
Vol 28 (3) ◽  
pp. 149-165 ◽  
Author(s):  
Seng Liang ◽  
Manjit Singh ◽  
Lay-Harn Gam
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Protein Profile ◽  
Female Breast Cancer ◽  
Female Mortality ◽  
Normal Tissues ◽  
Infiltrating Ductal Carcinoma ◽  
Female Breast ◽  
Proteomic Approach ◽  
Breast Tissues

Female breast cancer is one of the leading causes of female mortality worldwide. In Malaysia, breast cancer is the most commonly diagnosed cancer in women. Of the women in Malaysia, the Chinese have the highest number of breast cancer cases, followed by the Indian and the Malay. The most common type of breast cancer is infiltrating ductal carcinoma (IDC). A proteomic approach was applied in this study to identify changes in the protein profile of cancerous tissues compared with normal tissues from 18 patients; 8 Chinese, 6 Malay and 4 Indian were analysed. Twenty-four differentially expressed hydrophilic proteins were identified. We evaluated the potential of these proteins as biomarkers for infiltrating ductal carcinoma based on their ethnic-specific expressions. Three of the upregulated proteins, calreticulin, 14-3-3 protein zeta and 14-3-3 protein eta, were found to be expressed at a significantly higher level in the cancerous breast tissues when compared with the normal tissues in cases of infiltrating ductal carcinoma. The upregulation in expression was particularly dominant in the Malay cohort.

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1987 ◽  
Vol 5 (1) ◽  
pp. 55-61 ◽  
Author(s):  
G M Clark ◽  
G W Sledge ◽  
C K Osborne ◽  
W L McGuire
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Recurrent Breast Cancer ◽  
Disease Recurrence ◽  
Axillary Lymph Nodes ◽  
Lymph Node Status ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Initial Recurrence ◽  
Er Positive

Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. However, both estrogen receptor (ER) status and axillary lymph node status at diagnosis, as well as the length of the disease-free interval, provide additional independent information for predicting patient survival after disease recurrence. Involved axillary lymph nodes at the time of initial diagnosis and/or lack of ERs may indicate a highly malignant tumor or a weak host defense, either of which might be related to short survival after relapse. Patients with ER-negative tumors recurred more often in visceral and soft-tissue sites, while patients with ER-positive tumors were more likely to recur in bony sites. However, for each metastatic site, receptor-positive patients had longer survival

Abstract P5-21-22: Palbociclib in highly pretreated metastatic ER-positive HER-2 negative breast cancer

2018 ◽  
Author(s):  
G Hoste ◽  
K Punie ◽  
H Wildiers ◽  
P Neven ◽  
P Berteloot ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Er Positive ◽  
Her 2

scholarly journals Metastatic Infiltrating Ductal Carcinoma of the Breast to the Colon: A Case Report and Literature Review

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Salih Samo ◽  
Muhammed Sherid ◽  
Husein Husein ◽  
Samian Sulaiman ◽  
Jeffrey V. Brower ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Carcinoma Of The Breast ◽  
Breast Cancer Metastases ◽  
Infiltrating Ductal Carcinoma ◽  
Ductal Breast Cancer ◽  
Cancer Metastases ◽  
History Of ◽  
Metastatic Involvement ◽  
Common Malignancy

True metastatic involvement of the colon is rare. Colonic metastases occur most commonly secondary to peritoneal metastases from intra-abdominal malignancies. Breast cancer is the most common malignancy that metastasizes hematogenously to the colon. Colonic metastatic disease mimics primary colonic tumors in its presentation. Colonic metastatic involvement is a poor prognostic sign, and the pathologist should be informed about the history of the primary breast cancer when examining the pathologic specimens. In this paper, we report a case of an ileocecal mass found to be histologically consistent with metastatic ductal breast cancer, and then we review the literature about breast cancer metastases to the gastrointestinal tract in general and colon in particular.

Sign in / Sign up

Export Citation Format

Share Document